Profile data is unavailable for this security.
About the company
Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.
- Revenue in CNY (TTM)109.74k
- Net income in CNY-229.37m
- Incorporated2013
- Employees179.00
- LocationHinova Pharmaceuticals IncCHENGDU 610041ChinaCHN
- Phone+86 2 885058465
- Fax+86 2 885058465
- Websitehttp://www.hinovapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xinjiang Bai Hua Cun Pharma Tech Co Ltd | 398.37m | 22.63m | 2.96bn | 787.00 | 130.86 | 4.04 | -- | 7.44 | 0.0593 | 0.0593 | 1.04 | 1.92 | 0.3728 | 1.48 | 1.87 | 506,185.00 | 2.12 | -4.59 | 2.99 | -6.24 | 47.94 | 24.09 | 5.68 | -18.40 | 1.43 | -- | 0.067 | -- | 5.54 | -2.50 | 137.33 | -- | -21.00 | -- |
Qingdao Vland Biotech INC | 1.26bn | 78.59m | 3.23bn | 1.57k | 40.95 | 1.88 | -- | 2.55 | 0.3116 | 0.3116 | 5.01 | 6.77 | 0.432 | 3.49 | 4.07 | 804,705.90 | 3.70 | 5.78 | 5.78 | 7.89 | 45.41 | 46.13 | 8.57 | 10.34 | 0.8687 | 22.88 | 0.3127 | 33.59 | 3.07 | 8.05 | 15.56 | -0.6507 | 24.68 | -6.89 |
Bide Pharmatech Co Ltd | 1.10bn | 77.60m | 3.40bn | 846.00 | 43.18 | 1.72 | -- | 3.09 | 0.8669 | 0.8669 | 12.25 | 21.73 | 0.4687 | 1.02 | 4.83 | 1,301,939.00 | 3.26 | -- | 3.73 | -- | 38.92 | -- | 6.96 | -- | 5.04 | -- | 0.043 | -- | 30.94 | -- | -24.94 | -- | -- | -- |
Hinova Pharmaceuticals Inc | 109.74k | -229.37m | 3.55bn | 179.00 | -- | 2.78 | -- | 32,391.65 | -2.32 | -2.32 | 0.0011 | 12.92 | 0.00007 | 7.25 | 0.0054 | 613.07 | -14.92 | -31.86 | -16.50 | -37.18 | -400.96 | -- | -209,012.60 | -25,578.24 | 7.21 | -- | 0.036 | -- | -100.00 | -- | 2.44 | -- | 124.37 | -- |
Shanghai Aladdin Biochemical Tech Co Ltd | 455.90m | 102.18m | 3.71bn | 566.00 | 30.43 | 3.62 | -- | 8.14 | 0.4397 | 0.4397 | 1.82 | 3.70 | 0.2866 | 0.3598 | 8.66 | 805,473.80 | 6.79 | 8.83 | 7.81 | 9.61 | 61.34 | 61.49 | 23.70 | 26.85 | 3.13 | -- | 0.2729 | 45.71 | 6.55 | 19.36 | -7.48 | 9.95 | 31.41 | -- |
Jiangsu Yahong Meditech Co Ltd | 94.17m | -398.99m | 3.76bn | 394.00 | -- | 1.71 | -- | 39.95 | -0.6969 | -0.6969 | 0.1645 | 3.85 | 0.0366 | 11.12 | 5.92 | 239,007.60 | -15.55 | -15.80 | -16.49 | -16.48 | 77.85 | 55.32 | -424.48 | -9,445.91 | 10.12 | -- | 0.0711 | -- | 52,594.79 | -- | -62.42 | -- | 64.28 | -- |
HitGen Inc | 410.39m | 45.10m | 4.61bn | 452.00 | 101.83 | 3.40 | -- | 11.23 | 0.1129 | 0.1129 | 1.03 | 3.38 | 0.2418 | 7.22 | 5.05 | 907,947.10 | 2.60 | 4.63 | 2.76 | 5.10 | 49.20 | 58.89 | 10.77 | 20.66 | 16.53 | 24.49 | 0.1431 | 19.14 | 12.64 | 19.69 | 61.16 | -1.96 | -6.12 | -- |
Beijing Kawin Technol Sha-hld Co Ltd | 1.44bn | 120.57m | 4.82bn | 584.00 | 39.23 | 2.69 | -- | 3.35 | 0.7192 | 0.7192 | 8.56 | 10.48 | 0.6254 | 1.58 | 3.70 | 2,465,474.00 | 6.48 | 5.31 | 8.22 | 6.76 | 83.02 | 86.02 | 10.36 | 8.10 | 3.22 | -- | 0.103 | 43.82 | 21.73 | 14.87 | 39.71 | 21.04 | 25.01 | -- |
Shanghai Medicilon Inc | 1.01bn | -269.57m | 4.85bn | 2.42k | -- | 1.99 | -- | 4.78 | -2.01 | -2.01 | 7.68 | 18.05 | 0.365 | 6.19 | 1.32 | 390,279.00 | -9.70 | 9.34 | -12.49 | 11.73 | 1.81 | 36.71 | -26.57 | 14.93 | 2.87 | -- | 0.0923 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
Beijing Sun-Novo Pharma Research Co Ltd | 1.03bn | 215.33m | 4.88bn | 1.39k | 22.65 | 4.47 | -- | 4.72 | 1.92 | 1.92 | 9.23 | 9.73 | 0.5919 | 32.80 | 1.65 | 754,698.20 | 11.73 | 12.99 | 18.65 | 21.70 | 56.06 | 53.93 | 19.82 | 21.34 | 1.98 | 35.78 | 0.3065 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
Holder | Shares | % Held |
---|---|---|
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.63m | 20.45% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 4.00m | 17.66% |
China Fund Management Co., Ltd.as of 31 Dec 2023 | 2.11m | 9.33% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.31m | 5.78% |
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.07m | 4.73% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 514.40k | 2.27% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 359.59k | 1.59% |
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 343.09k | 1.52% |
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 320.72k | 1.42% |
ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023 | 310.80k | 1.37% |